查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1908709

美国口服固体製剂CDMO市场规模、份额和趋势分析报告：产品、机制、治疗效果、最终用途和细分市场预测（2025-2033年）

U.S. Oral Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Product (Tablets, Capsules, Powders), By Mechanism (Immediate, Delayed), By Drug Potency, By End-use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 162 Pages | 商品交期: 2-10个工作天内

价格

美国口服固体製剂CDMO市场概述

2024年美国口服固体製剂CDMO市场规模估计为116.2亿美元，预计2033年将达到239.9亿美元。

预计从 2025 年到 2033 年，该市场将以 8.63% 的年复合成长率（CAGR）成长。市场成长的驱动力是人们越来越关注复杂配方，以及越来越重视成本效益和上市速度。

此外，监管合规性和品质保证标准的加强，以及小规模和虚拟製药公司的扩张，正在推动市场成长。难溶性原料药和先进标靶给药系统的日益普及，显着提升了对口服固体製剂（OSD）配方专业知识的需求。能够管理复杂配方（例如缓释片、复方组合药物和奈米技术药物递送系统）的美国合约研发生产机构（CDMO）正在赢得全球製药公司的外包合约。例如，2025年8月，Piramal Pharma Solutions在宾州开设了一家专门的OSD生产工厂，投资数百万美元，旨在透过先进的製粒、压片、片剂生产和包衣技术，支援复方组合药物的生产并提高营运效率。透过提供先进的服务，CDMO可以帮助客户克服配方难题，提高疗效并确保产品稳定性。这使它们脱颖而出，优化了工厂产能，并与寻求高价值解决方案的创新者建立了长期伙伴关係。

此外，製药公司面临着加快产品上市速度、降低营运成本和确保高品质标准的压力。将口服固体製剂(OSD) 的生产外包给美国本土的合约研发生产机构 (CDMO) 可以让企业利用其专业知识、优化资源并简化供应链，从而实现更快、更有效率的产品开发。例如，2024 年 9 月，赛默飞世尔科技投资 2,200 万美元，用于扩建其位于俄亥俄州辛辛那提和奥勒冈州本德的 OSD 研发和生产基地。此次扩建增强了其 CDMO 和合约研究机构 (CRO) 网路内的早期研发、製剂设计和测试能力。此外，与 CDMO 合作还能帮助企业避免维修成本。因此，能够提供从製剂开发、规模化生产到商业化生产和包装等全方位服务的 CDMO，在加速产品上市方面具有策略优势。

此外，美国食品药物管理局 (FDA) 的严格监管和不断发展的全球品质标准是推动製药企业将口服固体製剂(OSD) 生产外包给美国合约研发生产机构 (CDMO) 的关键因素。维持内部监管专业知识和基础设施成本高昂且复杂，因此製药公司倾向于依赖拥有良好合规记录的合作伙伴。此外，符合现行药品生产品质管理规范 (cGMP)、随时准备接受 FDA 检查并满足国际品质要求的 CDMO 能够降低风险、审核准备就绪并确保产品安全性。这种卓越的监管能力能够建立客户信任，并将 CDMO 定位为首选的外包合作伙伴。因此，企业可以期待持续的合约、长期的合作关係以及市场信誉的提升。

目录

第一章调查方法和范围

第二章执行摘要

第三章美国口服固体製剂CDMO市场变数、趋势与范围

  • 市场谱系展望
    • 母市场展望
    • 相关市场展望
  • 市场动态
  • 科技趋势
  • 定价模式分析
  • 关税影响分析
  • 价值链分析
    • 供应趋势
    • 需求趋势
  • 市场分析工具
    • 波特五力分析
    • PESTEL 分析与 SWOT 分析

第四章：美国口服固体製剂CDMO市场：产品估算与趋势分析

  • 美国口服固体製剂CDMO市场：产品差异分析
  • 美国口服固体製剂CDMO市场规模及产品趋势分析（2021-2033年）
  • 药片
    • 压缩片剂
    • 口溶锭（ODT）
    • 咀嚼片
    • 双层或三层片剂
    • 舌下或口腔片
    • 其他的
  • 胶囊
    • 硬明胶胶囊
    • 软胶囊
  • 粉末
  • 颗粒
  • 其他的

第五章：美国口服固体製剂CDMO市场：机制评估与趋势分析

  • 美国口服固体製剂CDMO市场：依机制区分的差异分析
  • 美国口服固体製剂CDMO市场规模及趋势分析（依作用机制划分，2021-2033年）
  • 即时发布
  • 缓释性
  • 控释

第六章：美国口服固体製剂CDMO市场：依技术分類的估算与趋势分析

  • 美国口服固体製剂CDMO市场：技术变革分析
  • 美国口服固体製剂CDMO市场规模及趋势分析（依技术划分，2021-2033年）
  • 造粒技术
  • 压缩技术
  • 封装技术
  • 涂层技术
  • 连续製造技术
  • 其他的

第七章：美国口服固体製剂CDMO市场：药物疗效评估与趋势分析

  • 美国口服固体製剂CDMO市场：药物疗效差异分析
  • 美国口服固体製剂CDMO市场规模及趋势分析（依治疗适应症划分，2021-2033年）
  • 高效药物
  • 中等效力药物
  • 低效药物

第八章：美国口服固体製剂CDMO市场：依最终用途分類的估算与趋势分析

  • 美国口服固体製剂CDMO市场：依最终用途分類的差异分析
  • 美国口服固体製剂CDMO市场规模及应用趋势分析（2021-2033年）
  • 大公司
  • 小规模
  • 其他的

第九章 竞争情势

  • 主要参与者的分类
    • Market Leaders
    • Emerging Players
  • 2024年市场占有率/评估分析（热力图分析）
  • 公司简介
    • Lonza
    • Thermo Fisher Scientific Inc.
    • Cambrex Corporation
    • Catalent Inc.
    • Siegfried Holding AG
    • Recipharm AB
    • CordenPharma International
    • Boehringer Ingelheim
    • Piramal Pharma Solutions
    • Aenova Group
    • Almac Group
    • Jubilant Pharmova Limited
    • AbbVie Contract Manufacturing
    • Quotient Sciences
    • SPI Pharma
    • DPT Laboratories Ltd.
    • Alcami Corporation
Product Code: GVR-4-68040-831-5

U.S. Oral Solid Dosage CDMO Market Summary

The U.S. oral solid dosage CDMO market size was estimated at USD 11.62 billion in 2024 and is projected to reach USD 23.99 billion in 2033, growing at a CAGR of 8.63% from 2025 to 2033. The market growth is driven by an increasing focus on complex formulations, along with a growing emphasis on cost efficiency and speed-to-market.

In addition, increasing regulatory compliance and quality assurance standards, as well as the expansion of small and virtual pharma companies, are propelling market growth. The growing prevalence of poorly soluble APIs and advanced targeted drug delivery systems has driven significant demand for specialized expertise in oral solid dosage (OSD) formulations. U.S. contract development and manufacturing organizations (CDMOs) that can manage complex formulations such as controlled-release tablets, fixed-dose combinations, and nanotechnology in drug delivery are attracting outsourcing contracts from global pharmaceutical companies. For instance, in August 2025, Piramal Pharma Solutions inaugurated a dedicated OSD suite in Pennsylvania, investing millions to support fixed-dose combination production and enhance operational efficiency through advanced granulation, compression, tableting, and coating capabilities. Thus, by offering these sophisticated services, CDMOs help clients overcome formulation challenges, improve therapeutic efficacy, and ensure product stability, differentiating themselves, optimizing facility capacity, and building long-term partnerships with innovators seeking high-value solutions.

Further, pharmaceutical companies face pressure to reduce time-to-market, operational costs, and ensure high-quality standards for their products. Outsourcing oral solid dosage (OSD) manufacturing to U.S.-based CDMOs allows companies to utilize specialized expertise, optimize resources, and streamline supply chains, enabling faster and more efficient product development. For instance, in September 2024, Thermo Fisher Scientific invested USD 22 million to expand OSD development and manufacturing at Cincinnati, Ohio, and Bend, Oregon, enhancing early-stage R&D, formulation, and testing capabilities within its CDMO and CRO network. Furthermore, by collaborating with CDMOs, companies can avoid the costs of building and maintaining in-house facilities and regulatory capabilities. Therefore, CDMOs that provide comprehensive services, from formulation development and scale-up to commercial manufacturing and packaging, offer a strategic advantage for accelerating product launches.

Moreover, stringent FDA regulations and evolving global quality standards are major drivers for outsourcing oral solid dosage (OSD) manufacturing to U.S. CDMOs. Maintaining in-house regulatory expertise and infrastructure is expensive and complex, prompting pharmaceutical companies to rely on partners with proven compliance track records. In addition, CDMOs adhering to cGMP, FDA inspection readiness, and international quality requirements provide risk mitigation, audit preparedness, and consistent product safety. This regulatory excellence builds client trust and positions CDMOs as preferred outsourcing partners. As a result, companies gain recurring contracts, long-term collaborations, and enhanced market credibility.

U.S. Oral Solid Dosage CDMO Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. oral solid dosage CDMO market report based on product, mechanism, technology, drug potency, and end use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Tablets
    • Compressed Tablets
    • Orally Disintegrating Tablets (ODT)
    • Chewable Tablets
    • Bi-layer or Tri-layer Tablets
    • Sublingual or Buccal Tablets
    • Others
  • Capsules
    • Hard Gelatin Capsules
    • Soft Gelatin Capsules
  • Powders
  • Granules
  • Others
  • Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
  • Immediate Release
  • Delayed Release
  • Controlled Release
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Granulation Technologies
  • Compression Technologies
  • Encapsulation Technologies
  • Coating Technologies
  • Continuous Manufacturing Technologies
  • Others
  • Drug Potency Outlook (Revenue, USD Million, 2021 - 2033)
  • High Potent Drugs
  • Moderate Potent Drugs
  • Low Potent Drugs
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Large Size Companies
  • Medium & Small Size Companies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mechanism
    • 1.2.3. Technology
    • 1.2.4. Drug Potency
    • 1.2.5. End use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Top-Down Analysis
    • 1.7.3. Botton-Up Approach
    • 1.7.4. Multivariate Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Oral Solid Dosage CDMO Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Demand for One-Stop-Shop CMOs
      • 3.2.1.2. Growing Demand for Generic and Specialty Oral Solid Drugs
      • 3.2.1.3. Expansion of Outsourced Pharmaceutical Manufacturing
      • 3.2.1.4. Technological Advancements in Formulation and Process Development
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Strict Approval Criteria by Regulatory Authorities
      • 3.2.2.2. Lack of Experienced Technical Staff, Physical Capability, and Equipment Capacity
      • 3.2.2.3. Increasing Need for Biosimilars and Their Prominence in Addressing Cancer & Other Medical Conditions
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Value Chain Analysis
    • 3.6.1. Supply Trends
    • 3.6.2. Demand Trends
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Force Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Oral Solid Dosage CDMO Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Oral Solid Dosage CDMO Market Segment Dashboard
  • 4.2. U.S. Oral Solid Dosage CDMO Market: Product Movement Analysis
  • 4.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Tablets
    • 4.4.1. Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Compressed Tablets
      • 4.4.2.1. Compressed Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Orally Disintegrating Tablets (ODT)
      • 4.4.3.1. Orally Disintegrating Tablets (ODT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Chewable Tablets
      • 4.4.4.1. Chewable Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Bi-layer or Tri-layer Tablets
      • 4.4.5.1. Bi-layer or Tri-layer Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.6. Sublingual or Buccal Tablets
      • 4.4.6.1. Sublingual or Buccal Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Capsules
    • 4.5.1. Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Hard Gelatin Capsules
      • 4.5.2.1. Hard Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Soft Gelatin Capsules
      • 4.5.3.1. Soft Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Powder
    • 4.6.1. Powder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Granules
    • 4.7.1. Granules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Oral Solid Dosage CDMO Market: Mechanism Estimates & Trend Analysis

  • 5.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
  • 5.2. U.S. Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
  • 5.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Mechanism, 2021 to 2033 (USD Million)
  • 5.4. Immediate Release
    • 5.4.1. Immediate Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Delayed Release
    • 5.5.1. Delayed Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Controlled Release
    • 5.6.1. Controlled Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Oral Solid Dosage CDMO Market: Technology Estimates & Trend Analysis

  • 6.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
  • 6.2. U.S. Oral Solid Dosage CDMO Market: Technology Movement Analysis
  • 6.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 6.4. Granulation Technologies
    • 6.4.1. Granulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Compression Technologies
    • 6.5.1. Compression Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Encapsulation Technologies
    • 6.6.1. Encapsulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Coating Technologies
    • 6.7.1. Coating Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Continuous Manufacturing Technologies
    • 6.8.1. Continuous Manufacturing Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Oral Solid Dosage CDMO Market: Drug Potency Estimates & Trend Analysis

  • 7.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
  • 7.2. U.S. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
  • 7.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by Drug Potency, 2021 to 2033 (USD Million)
  • 7.4. High Potent Drugs
    • 7.4.1. High Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Moderate Potent Drugs
    • 7.5.1. Moderate Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Low Potent Drugs
    • 7.6.1. Low Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Oral Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

  • 8.1. U.S. Oral Solid Dosage CDMO Market: Segment Dashboard
  • 8.2. U.S. Oral Solid Dosage CDMO Market: End Use Movement Analysis
  • 8.3. U.S. Oral Solid Dosage CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 8.4. Large Size Companies
    • 8.4.1. Large Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Medium & Small Size Companies
    • 8.5.1. Medium & Small Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Others
    • 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Key Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
  • 9.3. Company Profiles
    • 9.3.1. Lonza
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Cambrex Corporation
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Catalent Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Siegfried Holding AG
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Recipharm AB
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. CordenPharma International
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Boehringer Ingelheim
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Piramal Pharma Solutions
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Aenova Group
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Almac Group
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Jubilant Pharmova Limited
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. AbbVie Contract Manufacturing
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Quotient Sciences
      • 9.3.14.1. Company Overview
      • 9.3.14.2. Financial Performance
      • 9.3.14.3. Service Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. SPI Pharma
      • 9.3.15.1. Company Overview
      • 9.3.15.2. Financial Performance
      • 9.3.15.3. Service Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. DPT Laboratories Ltd.
      • 9.3.16.1. Company Overview
      • 9.3.16.2. Financial Performance
      • 9.3.16.3. Service Benchmarking
      • 9.3.16.4. Strategic Initiatives
    • 9.3.17. Alcami Corporation
      • 9.3.17.1. Company Overview
      • 9.3.17.2. Financial Performance
      • 9.3.17.3. Service Benchmarking
      • 9.3.17.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 4. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Mechanism, 2021 - 2033 (USD Million)
  • Table 5. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by Drug Potency, 2021 - 2033 (USD Million)
  • Table 6. U.S. Oral Solid Dosage CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. Oral Solid Dosage CDMO Market Dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. Oral Solid Dosage CDMO Market: Product Outlook And Key Takeaways
  • Fig. 20 U.S. Oral Solid Dosage CDMO Market: Product Movement Analysis
  • Fig. 21 Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Compressed Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Orally Disintegrating Tablets (ODT) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Chewable Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Bi-layer or Tri-layer Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Sublingual or Buccal Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Hard Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Soft Gelatin Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Powders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Granules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Oral Solid Dosage CDMO Market: Mechanism Outlook And Key Takeaways
  • Fig. 35 U.S. Oral Solid Dosage CDMO Market: Mechanism Movement Analysis
  • Fig. 36 Immediate Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Delayed Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Controlled Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Oral Solid Dosage CDMO Market: Technology Outlook And Key Takeaways
  • Fig. 40 U.S. Oral Solid Dosage CDMO Market: Technology Movement Analysis
  • Fig. 41 Granulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Compression Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Encapsulation Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Coating Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Continuous Manufacturing Technologies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Oral Solid Dosage CDMO Market: Drug Potency Outlook And Key Takeaways
  • Fig. 48 U.S. Oral Solid Dosage CDMO Market: Drug Potency Movement Analysis
  • Fig. 49 High Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Moderate Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Low Potent Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 U.S. Oral Solid Dosage CDMO Market: End Use Outlook And Key Takeaways
  • Fig. 53 U.S. Oral Solid Dosage CDMO Market: End Use Movement Analysis
  • Fig. 54 Large Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Medium & Small Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)